Otsuka Pakistan Limited manufactures, markets, and distributes intravenous infusions in Pakistan and Afghanistan. The company offers intravenous solutions, including electrolyte and standard solutions, ampoules, OTSUZOL, and ciprofloxacin and OTSUMOL infusion products; medical devices, such as urea breath test systems, plasline solutions, sirolimus eluting coronary stent system, eucaLIMUS, and eucaVI; clinical nutrition products comprising aminoleban oral, aminovel 600, pan-amin G, aminoleban injection, and proten gold; and therapeutic drugs, which include pletaal and mucosta tablets, as well as oral rehydration therapy supplement for urinary tract. It engages in the trading of pharmaceutical products, nutritional foods, and medical equipment. Further, the company provides medical devices, including Made in Germany CE-marked drug-eluting coronary stents, PTCA balloon catheters, and other coronary angioplasty accessories and electrophysiology products. Otsuka Pakistan Limited was incorporated in 1988 and is headquartered in Karachi, Pakistan.
Metrics to compare | OTSU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOTSUPeersSector | |
---|---|---|---|---|
P/E Ratio | 104.6x | 14.6x | −0.5x | |
PEG Ratio | −1.63 | 0.15 | 0.00 | |
Price/Book | 4.4x | 2.7x | 2.6x | |
Price / LTM Sales | 0.9x | 1.6x | 3.2x | |
Upside (Analyst Target) | - | 31.3% | 40.5% | |
Fair Value Upside | Unlock | 16.7% | 4.4% | Unlock |